Estradiol/Norethindrone Acetate drug is used after menopause to reduce moderate to severe hot flushes, treat moderate to severe menopausal changes in and around the vagina, and help reduce your chances of getting osteoporosis (thin weak bones).

The global Estradiol/Norethindrone Acetate drug market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Estradiol/Norethindrone Acetate drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Estradiol/Norethindrone Acetate drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Estradiol/Norethindrone Acetate drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Estradiol/Norethindrone Acetate drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novo Nordisk
Amneal
Lupin Pharmaceuticals
Noven Pharmaceuticals
Breckenridge Pharmaceutical
Teva
Mylan
Accord Hlthcare

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
1.0 mg/0.5 mg
0.5 mg/0.1mg

Segment by Application
prevention of osteoporosis
other symptoms associated w/postmenopause